January 30, 2020
CDR-Life moves into larger facilities in the Bio-Technopark, Schlieren
ZURICH, Switzerland, January 30, 2020 – CDR-Life inc. has moved into new fully equipped laboratory facilities in Wagistrasse 27, 8952 Schlieren-Zurich. This move positions the company to grow and to advance it’s promising pipeline of game-changing oncology and ophthalmology therapies into clinical trials over the coming years.
October 28, 2019
CDR-Life Enters Research Collaboration with University Hospital Zurich
Ex vivo studies for the prediction of clinical response in multiple myeloma.
ZURICH, Switzerland, October 28, 2019 – CDR-Life inc. has entered a research collaboration with Prof. Markus G. Manz, MD, Head of Medical Oncology and Hematology at University Hospital and University of Zurich, to further test CDR-Life’s trispecific antibodies on primary cancer patient tissue.
The collaboration will combine strong clinical know-how and patient sample access at the University Hospital with CDR-Life’s deep expertise in developing unconventional antibody- based therapies.
“CDR-Life’s trispecific LocATE antibodies are potentially transformative in the field of immunotherapies,” said Prof. Manz. “We are looking forward to help validate the promise of this novel approach.”
“Patient ex vivo testing has been shown to be highly predictive of clinical outcome” said Leonardo Borras, Chief Science Officer at CDR-Life. “Access to world-class expertise and real patient samples for testing our novel antibodies is very powerful.”
June 3, 2019
CDR-Life Presents Results at ASCO
Local activator and T cell engager (LocATE) selectively blocks PD-L1 at the cytolytic synapse for deeper responses in multiple myeloma.
May 23, 2018
CDR-Life Enters Research Collaboration with ETH Zürich
Ex vivo drug response profiling of novel immunotherapies in patient biopsies.
ZURICH, Switzerland, May 23, 2018 – CDR-Life inc. has entered a research collaboration with Prof. Berend Snijder, ETH Zürich, to study the effect of their novel trispecific T cell engagers on cancer patient samples using pharmacoscopy, a human ex vivodrug screening technology.
The collaboration will use synergies between the modular multispecific immunotherapies from CDR-Life and the pharmacoscopy technology from the Snijder laboratory to explore both the biology that drives immune cell engagement and the principles that guide optimal drug design.
“CDR-Life’s multispecific molecules are ideal together with our pharmacoscopy technology to deduce impactful learnings about the biology of immune cell engagement” said Prof. Snijder.
“Pharmacoscopy has been shown to be highly predictive of clinical outcome,” said Dr. Christian Leisner, chief executive officer of CDR-Life. “This is contrary to many in vitro and in vivo methods and makes it a powerful tool to understand the impact of our trispecific immunotherapies.”
May 8, 2017
CDR-Life Announces Formation of Scientific Advisory Board
Inaugural Members Include Leading Ophthalmic Luminaries from the United States and Europe.
ZURICH, Switzerland, May 8, 2017 – CDR-Life Inc., a biotechnology company focused on advancing therapeutic antibody fragments in the areas of ophthalmology and oncology, today announced the formation of a Scientific Advisory Board (SAB) comprised of academic and industry experts in the field of ophthalmology from both the United States and Europe.
The Scientific Advisory Board will serve as a vital strategic resource to the Company to develop novel treatments for ophthalmic diseases. In addition to guiding CDR-Life’s research and development activities, including clinical trial designs, the SAB will also identify new target indications and will evaluate strategic assets that leverage the management’s expertise in therapeutic antibody fragments.
“We are pleased to welcome this diverse group of ophthalmic experts, representing thought leaders from clinical practice and academia, to our newly formed Scientific Advisory Board,” said Dominik Escher, PhD, executive chairman of CDR-Life. “The expertise that they bring to our executive team and Board will prove invaluable as we refine our clinical plan and work to bring novel therapies to patients in need.”
“We believe our approach to developing novel therapeutic antibody fragments holds significant potential in ophthalmology and oncology where unmet medical needs persist,” said Christian Leisner, PhD, chief executive officer of CDR-Life. “We look forward to leveraging the varied experience of our new Scientific Advisory Board as we pursue the efficient development of our proprietary molecules.”
The Advisory Board members include:
Reza Dana, MD – Director at Harvard Medical School, Department of Ophthalmology, Cornea Center of Excellence
Pravin Dugel, MD – Managing Partner, Retinal Consultants of Arizona (RCA)
Frank G. Holz, MD – Chairman and Professor at the Department of Ophthalmology, University of Bonn
Stephan Michels, MD – Professor at the University of Zurich and Vice Chair at City Hospital Triemli, Zurich, Switzerland
Manfred Zierhut, MD – Professor at University Hospital of Tuebingen, Germany